Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging

Fig. 2

89Zr-trastuzumab binding and uptake decreases upon dasatinib treatment. Internalization and binding assays of 89Zr-trastuzumab on BT-474 and JIMT-1 cells treated with dasatinib half maximal inhibitory concentration (IC50) from 0 to 48 h showed a decrease in probe internalization and binding over time (a). Treatment and imaging scheme illustrates treatment of tumors for 7 days and/or 14 days with dasatinib followed by positron emission tomography (PET) with fluorodeoxyglucose (18F-FDG). 89Zr-trastuzumab was administered a day after with imaging acquired 48 h post injection (b). Tx, treatment; d, days

Back to article page
\